Comparing patterns and costs of schizophrenia care in EPSILON study

Acta Psychiatrica Scandinavica 105, 42-54

DOI: 10.1034/j.1600-0447.2002.\_10310.x

Citation Report

#	Article	IF	CITATIONS
1	Economic impact of personality disorders in UK primary care attenders. British Journal of Psychiatry, 2002, 181, 62-66.	1.7	66
2	Provision of services for people with schizophrenia in five European regions. Social Psychiatry and Psychiatric Epidemiology, 2002, 37, 465-474.	1.6	42
3	Measuring the parental, service and cost impacts of children with autistic spectrum disorder: a pilot study. Journal of Autism and Developmental Disorders, 2003, 33, 395-402.	1.7	145
5	Unit costs in international economic evaluations: resource costing of the Schizophrenia Outpatient Health Outcomes Study. Acta Psychiatrica Scandinavica, 2003, 107, 41-47.	2.2	6
6	The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatrica Scandinavica, 2003, 107, 222-232.	2.2	98
7	A longitudinal analysis of the impact of social and clinical characteristics on the costs of schizophrenia treatment. Acta Psychiatrica Scandinavica, 2003, 107, 351-360.	2.2	22
8	Integrated care in schizophrenia: a 2-year randomized controlled study of two community-based treatment programs. Acta Psychiatrica Scandinavica, 2003, 107, 415-423.	2.2	99
9	Cost-effectiveness of the HIT programme in patients with schizophrenia and persistent auditory hallucinations. Acta Psychiatrica Scandinavica, 2003, 107, 361-368.	2.2	19
11	Depression status, medical comorbidity and resource costs. British Journal of Psychiatry, 2003, 183, 121-131.	1.7	83
13	Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. British Journal of Psychiatry, 2003, 182, 505-508.	1.7	53
14	Describing, explaining or predicting mental health care costs: a guide to regression models. British Journal of Psychiatry, 2003, 183, 398-404.	1.7	76
15	Premorbid, psychosocial and clinical predictors of the costs of schizophrenia and other psychoses. British Journal of Psychiatry, 2004, 184, 517-525.	1.7	42
17	The effect of previous psychiatric history on the cost of care: a comparison of various regression models. Acta Psychiatrica Scandinavica, 2004, 109, 132-139.	2.2	21
18	Effect of Second-Generation Antipsychotics on Employment and Productivity in Individuals with Schizophrenia. Pharmacoeconomics, 2004, 22, 701-718.	1.7	34
19	Routine outcome monitoring in clinical practice: service and non-service costs of psychiatric patients attending a Community Mental Health Centre in Italy. European Psychiatry, 2004, 19, 469-477.	0.1	5
20	Non-adherence to antipsychotic medication regimens: Associations with resource use and costs. British Journal of Psychiatry, 2004, 184, 509-516.	1.7	158
21	Cost of psychotic disorders in Europe. European Journal of Neurology, 2005, 12, 74-77.	1.7	39
22	Cost of disorders of the brain in Europe. European Journal of Neurology, 2005, 12, 1-27.	1.7	714

#	Article	IF	CITATIONS
24	Patterns of mental health service utilisation in Italy and Spain. Social Psychiatry and Psychiatric Epidemiology, 2005, 40, 149-159.	1.6	48
25	Needs and quality of life among patients with schizophrenia in five European centres. Social Psychiatry and Psychiatric Epidemiology, 2005, 40, 628-634.	1.6	38
26	The European Schizophrenia Cohort. Social Psychiatry and Psychiatric Epidemiology, 2005, 40, 707-717.	1.6	58
27	Does Additional Care Provided by a Consumer Self-Help Group Improve Psychiatric Outcome? A Study in an Italian Community-based Psychiatric Service. Community Mental Health Journal, 2005, 41, 705-720.	1.1	32
28	Impact of antipsychotic medication on the cost of schizophrenia. Expert Review of Pharmacoeconomics and Outcomes Research, 2005, 5, 39-57.	0.7	0
29	Antipsychotic drug-induced acute laryngeal dystonia: two case reports and a mini review. Journal of Psychopharmacology, 2005, 19, 307-311.	2.0	86
30	The economic burden of schizophrenia in Canada in 2004. Current Medical Research and Opinion, 2005, 21, 2017-2028.	0.9	131
31	ICAM G241A Polymorphism and Soluble ICAM-1 Serum Levels: Evidence for an Active Immune Process in Schizophrenia. NeuroImmunoModulation, 2005, 12, 54-59.	0.9	31
32	Size of burden of schizophrenia and psychotic disorders. European Neuropsychopharmacology, 2005, 15, 399-409.	0.3	516
33	Pharmacoeconomics of long-acting risperidone: Results and validity of cost-effectiveness models. Pharmacoeconomics, 2005, 23, 3-16.	1.7	31
34	Management of Schizophrenia. Disease Management and Health Outcomes, 2006, 14, 107-125.	0.3	11
35	Psychiatric services for people with severe mental illness across western Europe: what can be generalized from current knowledge about differences in provision, costs and outcomes of mental health care?. Acta Psychiatrica Scandinavica, 2006, 113, 9-16.	2.2	78
36	Satisfaction with treatment among patients with depressive and bipolar disorders. Social Psychiatry and Psychiatric Epidemiology, 2006, 41, 148-155.	1.6	26
37	The Camberwell assessment of need as an outcome measure in routine mental health care. Social Psychiatry and Psychiatric Epidemiology, 2006, 41, 728-733.	1.6	48
39	A framework for evidence-based mental health care and policy. Acta Psychiatrica Scandinavica, 2006, 114, 5-11.	2.2	24
40	Assessment of service use patterns in out-patients with schizophrenia: a Spanish study. Acta Psychiatrica Scandinavica, 2006, 114, 12-18.	2.2	13
41	Economic cost of severe antisocial behaviour in children - and who pays it. British Journal of Psychiatry, 2006, 188, 547-553.	1.7	154
42	Economic consequences of alternative medication strategies in first episode non-affective psychosis. European Psychiatry, 2007, 22, 347-353.	0.1	12

#	Article	IF	Citations
43	The Mental Health Economics European Network. Journal of Mental Health, 2007, 16, 157-165.	1.0	3
44	Trends in psychiatric hospitalisation of people with schizophrenia: A register-based investigation over the last three decades. Schizophrenia Research, 2007, 97, 68-78.	1.1	30
45	Health economic measures in schizophrenia research. British Journal of Psychiatry, 2007, 191, s42-s45.	1.7	11
46	Which factors affect the costs of psychiatric residential care? Findings from the Italian PROGRES study. Acta Psychiatrica Scandinavica, 2007, 115, 132-141.	2.2	9
47	Healthcare in schizophrenia: effectiveness and progress of a redesigned care network. BMC Health Services Research, 2007, 7, 129.	0.9	25
48	The functionality and economic costs of outpatients with schizophrenia in Taiwan. Psychiatry Research, 2008, 158, 306-315.	1.7	27
49	Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications. Clinical Therapeutics, 2008, 30, 1524-1539.	1.1	30
50	Cost of disorders of the brain in Denmark. Nordic Journal of Psychiatry, 2008, 62, 114-120.	0.7	14
51	Economic Burden of Schizophrenia in South Korea. Journal of Korean Medical Science, 2008, 23, 167.	1.1	49
52	Unmet Need for Mental Health Care in Schizophrenia: An Overview of Literature and New Data From a First-Admission Study. Schizophrenia Bulletin, 2009, 35, 679-695.	2.3	136
53	Why invest in early psychosis intervention services?. Microbial Biotechnology, 2009, 3, 237-238.	0.9	3
54	Cost of treatment of schizophrenia in six European countries. Schizophrenia Research, 2009, 111, 70-77.	1.1	58
55	Comparing the Cost Effectiveness of Risperidone and Olanzapine in the Treatment of Schizophrenia Using the Net-Benefit Regression Approach. Pharmacoeconomics, 2009, 27, 69-80.	1.7	10
56	Direct medical mental health care costs of schizophrenia in France, Germany and the United Kingdom $\hat{a} \in \text{``Findings from the European Schizophrenia Cohort (EuroSC). European Psychiatry, 2009, 24, 216-224.}$	0.1	27
57	Identifying patient-relevant endpoints among individuals with schizophrenia: An application of patient-centered health technology assessment. International Journal of Technology Assessment in Health Care, 2009, 25, 35-41.	0.2	45
59	Cost of disorders of the brain in Europe 2010. European Neuropsychopharmacology, 2011, 21, 718-779.	0.3	1,253
60	Economic Aspects of Peer Support Groups for Psychosis. Community Mental Health Journal, 2011, 47, 99-105.	1.1	22
61	Cognitive–behavioural therapy for persistent and recurrent psychosis in people with schizophrenia-spectrum disorder: cost-effectiveness analysis. British Journal of Psychiatry, 2011, 198, 59-65.	1.7	36

#	ARTICLE	IF	Citations
62	The difficult task of predicting the costs of community-based mental health care. A comprehensive case register study. Epidemiology and Psychiatric Sciences, 2011, 20, 245-256.	1.8	23
63	The costs of early intervention in psychosis: Restoring the balance. Australian and New Zealand Journal of Psychiatry, 2012, 46, 808-811.	1.3	17
64	Is Early Intervention for Psychosis Feasible and Effective?. Psychiatric Clinics of North America, 2012, 35, 613-631.	0.7	68
65	Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study. BMC Psychiatry, 2013, 13, 98.	1.1	19
66	Predictors of Hospitalization Two Years After Treatment for First-Episode Psychosis. Psychiatric Services, 2013, 64, 1230-1235.	1.1	10
67	Patient satisfaction with specialized mental health service for obsessive-compulsive disorder. Annals of General Psychiatry, 2013, 12, 41.	1.2	3
68	Supported employment: costâ€effectiveness across six European sites. World Psychiatry, 2013, 12, 60-68.	4.8	81
69	Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders. The Cochrane Library, 2014, 2014, CD001470.	1.5	9
70	A systematic review of the effect of community treatment orders on service use. Social Psychiatry and Psychiatric Epidemiology, 2014, 49, 651-663.	1.6	80
71	Group CBT for psychosis in acute care: a review of outcome studies. The Cognitive Behaviour Therapist, 2015, 8, .	0.4	3
72	Global economic burden of schizophrenia: a systematic review. Neuropsychiatric Disease and Treatment, 2016, 12, 357.	1.0	351
73	The association between continuity of care and readmission to hospital in patients with severe psychosis. Social Psychiatry and Psychiatric Epidemiology, 2016, 51, 1633-1643.	1.6	26
74	Burden of illness of people with persistent symptoms of schizophrenia: A multinational cross-sectional study. International Journal of Social Psychiatry, 2017, 63, 139-150.	1.6	28
75	Relationship between national mental health expenditure and quality of care in longer-term psychiatric and social care facilities in Europe: cross-sectional study. British Journal of Psychiatry, 2017, 211, 45-49.	1.7	2
76	Prevalence of mental diseases in Austria. Wiener Klinische Wochenschrift, 2018, 130, 141-150.	1.0	11
77	Does future resource input reflect need in firstâ€episode psychosis: Examining the association between individual characteristics and 5â€year costs. Microbial Biotechnology, 2019, 13, 1056-1061.	0.9	0
78	Standardised description of health and social care: A systematic review of use of the ESMS/DESDE (European Service Mapping Schedule/Description and Evaluation of Services and DirectoriEs). European Psychiatry, 2019, 61, 97-110.	0.1	35
79	Economic Cost of Schizophrenia in a Nigerian Teaching Hospital. Journal of Neurosciences in Rural Practice, 2019, 10, 39-47.	0.3	9

#	Article	IF	CITATIONS
80	Revisiting the concept of severe mental illness: severity indicators and healthcare spending in psychotic, depressive and dissociative disorders. Journal of Mental Health, 2020, 29, 670-676.	1.0	9
81	Costs of Mental Health Services in Czechia: Facilitating an Evidence-Based Reform of Psychiatric Care. Applied Health Economics and Health Policy, 2020, 18, 287-298.	1.0	7
82	Risk factors of hospitalization for any medical condition among patients with prior emergency department visits for mental health conditions. BMC Psychiatry, 2020, 20, 431.	1.1	10
83	Epidemiology of schizophrenia and its management over 8-years period using real-world data in Spain. BMC Psychiatry, 2020, 20, 149.	1.1	37
84	Appraisal of patient-level health economic models of severe mental illness: systematic review. British Journal of Psychiatry, 2022, 220, 86-97.	1.7	3
86	Disease Burden and Disability-Adjusted Life Years Due to Schizophrenia and Psychotic Disorders., 2010, , 1493-1507.		9
87	Evidence-based mental health services research. The contribution of some recent EU-funded projects. , $2004, 173-187$ .		2
88	Cost-effectiveness of mental health service systems in the European comparison., 2004,, 189-201.		5
89	Poor Adherence to Antipsychotic Medication in People with Schizophrenia: Diffusion, Consequences and Contributing Factors., 2014, , 1-84.		1
90	The Cost of Relapse in Schizophrenia. Pharmacoeconomics, 2017, 35, 921-936.	1.7	64
91	The Economic Costs of Progressive Supranuclear Palsy and Multiple System Atrophy in France, Germany and the United Kingdom. PLoS ONE, 2011, 6, e24369.	1.1	13
92	Economic evaluation and schizophrenia. Medical Psychiatry, 2009, , 347-361.	0.2	1
93	Overview and emerging trends. Indian Journal of Psychiatry, 2005, 47, 205.	0.4	5
94	Is Familiality Associated with Downward Occupation Drift in Schizophrenia?. Psychiatry Investigation, 2008, 5, 168.	0.7	5
95	Adaptation of activity-based-costing (ABC) to calculate unit costs in Mental Health Care in Spain. European Journal of Psychiatry, 2007, 21, .	0.7	6
96	Microarray- und immungenetische Untersuchungen bei Schizophrenie. , 2004, , 73-96.		0
97	Seguimiento ordinario de la evolución en la práctica clÃnica: costes de servicio y no de servicio de los pacientes psiquiátricos que asisten a un centro de Salud Mental Comunitaria en Italia. European Psychiatry (Ed Española), 2005, 12, 145-154.	0.0	0

#	Article	IF	CITATIONS
103	The EPSILON Study - a study of care for people with schizophrenia in five European centres. World Psychiatry, 2002, 1, 45-7.	4.8	7
105	The Impact of 90-day Physician Follow-up Care on the Risk of Readmission Following a Psychiatric Hospitalization. Administration and Policy in Mental Health and Mental Health Services Research, 2022, 49, 1047-1059.	1.2	2